Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SRA737 · CCT-245737

Small molecule · Inhibitor of checkpoint kinase 1 (CHEK1) · developed by Sierra Oncology LLC - a GSK company

Phase 1/2 Most advanced trial (none active)
GSK Developer
2 Registered trials

What is SRA737?

SRA737 is an orally bioavailable inhibitor of checkpoint kinase 1 (CHK1) that selectively binds CHK1, blocking its activity in DNA damage repair and cell cycle checkpoint control. It is studied in advanced solid tumors and non-Hodgkin's lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CCT-245737
Drug type
Small molecule
Targets
checkpoint kinase 1 (CHEK1)
Mechanism
Inhibitor of checkpoint kinase 1 (CHEK1)
Pathways
DNA damage repair, cell cycle checkpoint control, apoptosis
Therapy area
Oncology
Developer
Sierra Oncology LLC - a GSK company (GSK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
QB6LNL4NF6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02797964 Phase 1/2 Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) Completed GSK
NCT02797977 Phase 1/2 Advanced Solid Tumors Completed GSK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsAdvanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)

Other drugs acting on CHEK1

More from Sierra Oncology LLC - a GSK company

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.

Follow GSK, the company behind SRA737

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.